Skip to Content

Byfavo Dosage

Generic name: REMIMAZOLAM BESYLATE 2.5mg in 1mL
Dosage form: injection, powder, lyophilized, for solution

Medically reviewed by Last updated on Jul 20, 2020.

Important Dosage and Administration Instructions

BYFAVO can depress respiration. Continuously monitor patients for early signs of hypoventilation, airway obstruction, and apnea using capnography, pulse oximetry, and clinical assessment.

Only personnel trained in the administration of procedural sedation, and not involved in the conduct of the diagnostic or therapeutic procedure, should administer BYFAVO.

Administering personnel must be trained in the detection and management of airway obstruction, hypoventilation, and apnea, including the maintenance of a patent airway, supportive ventilation, and cardiovascular resuscitation.

Supplemental oxygen, resuscitative drugs, and age- and size-appropriate equipment for bag/valve/mask assisted ventilation must be immediately available during administration of BYFAVO. A benzodiazepine reversal agent should be immediately available.

Continuously monitor vital signs during sedation and through the recovery period [see Warnings and Precautions (5.1)] .

Peak sedation occurs approximately 3 to 3.5 minutes after an initial 5 mg intravenous injection of BYFAVO given over a 1-minute period [see Clinical Pharmacology (12.2)].

Titrate subsequent doses of BYFAVO on the basis of clinical judgment and assessment of the depth of sedation. If maintenance of procedural sedation is inadequate, consider alternative medications [see Clinical Studies (14)] .

Basic Dosing Information

  • Individualize BYFAVO dosing and titrate to desired clinical response.
  • In clinical studies, fentanyl 25 to 75 mcg was administered for analgesia prior to the first dose of BYFAVO. Supplemental doses of fentanyl were administered as needed for analgesia [see Clinical Studies (14)] .
  • Recommended dosing guidelines:
Induction of Procedural Sedation For adult patients: Administer 5 mg intravenously over a 1-minute time period.
For ASA-PS III and IV patients: Administer 2.5 mg to 5 mg intravenously over 1 minute based on the general condition of the patient.
Maintenance of Procedural Sedation (as needed) For adult patients: Administer 2.5 mg intravenously over 15 seconds.
At least 2 minutes must elapse prior to administration of any supplemental dose.
For ASA-PS III and IV patients: Administer 1.25 mg to 2.5 mg intravenously over 15 seconds.
At least 2 minutes must elapse prior to administration of any supplemental dose.


Reconstitution of BYFAVO (remimazolam) for injection

  • Strict aseptic technique must be maintained during handling of BYFAVO.
  • This product does not contain preservative.
  • Once removed from packaging, protect vials from light.
  • Each single-patient-use vial contains 20 mg BYFAVO lyophilized powder for reconstitution. The product must be prepared immediately before use.
  • To reconstitute, add 8.2 mL sterile 0.9% Sodium Chloride Injection, USP, to the vial, directing the stream of solution toward the wall of the vial. Gently swirl the vial (do not shake) until the contents are fully dissolved. The reconstituted product will deliver a final concentration of 2.5 mg/mL solution of BYFAVO.
  • Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Upon reconstitution, the solution should be a clear, colorless to pale yellow solution. Discard if particulate matter or discoloration is observed.
  • If not used immediately, reconstituted BYFAVO may be stored in the vial for up to 8 hours under controlled room temperature at 20°C to 25°C (68°F to 77°F). After 8 hours, any unused portion must be discarded.

Administration with Other Fluids

  • BYFAVO has been shown to be compatible with the following fluids: 0.9% Sodium Chloride Injection, USP, 5% Dextrose Injection, USP, 20% Dextrose Injection, USP, 5% Dextrose and 0.45% Sodium Chloride Injection, USP, and Ringer's Solution. Do not mix BYFAVO with other drugs or fluids prior to administration.
  • BYFAVO compatibility with other agents has not been adequately evaluated.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

More about Byfavo (remimazolam)

Professional resources

Related treatment guides